CO2022015313A2 - Variantes de cápsides de aav y usos de los mismos - Google Patents
Variantes de cápsides de aav y usos de los mismosInfo
- Publication number
- CO2022015313A2 CO2022015313A2 CONC2022/0015313A CO2022015313A CO2022015313A2 CO 2022015313 A2 CO2022015313 A2 CO 2022015313A2 CO 2022015313 A CO2022015313 A CO 2022015313A CO 2022015313 A2 CO2022015313 A2 CO 2022015313A2
- Authority
- CO
- Colombia
- Prior art keywords
- protein variants
- capsid protein
- disclosure
- aav
- delivery
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Aspectos de la divulgación se refieren a composiciones y métodos para entrega de un transgén (por ejemplo, un transgén que codifica uno o más productos génicos) a una célula blanco. La divulgación se basa, en parte, en variantes de la proteína de la cápside del virus adenoasociado (AAV) caracterizadas por tropismos para ciertos tipos de células (por ejemplo, neuronas, células musculares, células óseas, células cardíacas, etc.). En algunas modalidades, los AAV recombinantes (rAAV) que comprenden las variantes de la proteína de la cápside (por ejemplo, AAVv66, SEQ ID NO: 1) se empacan de manera más eficiente que los rAAV que tienen ciertas proteínas de la cápside de AAV tipo silvestre. Los métodos para entrega de un rAAV que comprende las variantes de proteína de la cápside de AAV también se describen en la divulgación.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063003143P | 2020-03-31 | 2020-03-31 | |
PCT/US2021/024837 WO2021202494A1 (en) | 2020-03-31 | 2021-03-30 | Aav capsids variants and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022015313A2 true CO2022015313A2 (es) | 2023-02-16 |
Family
ID=75870702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0015313A CO2022015313A2 (es) | 2020-03-31 | 2022-10-27 | Variantes de cápsides de aav y usos de los mismos |
Country Status (14)
Country | Link |
---|---|
US (1) | US20230138766A1 (es) |
EP (1) | EP4126911A1 (es) |
JP (1) | JP2023529054A (es) |
KR (1) | KR20230113689A (es) |
CN (1) | CN115698039A (es) |
AR (1) | AR122404A1 (es) |
AU (1) | AU2021248577A1 (es) |
BR (1) | BR112022019304A2 (es) |
CA (1) | CA3177182A1 (es) |
CO (1) | CO2022015313A2 (es) |
IL (1) | IL296765A (es) |
MX (1) | MX2022012279A (es) |
TW (1) | TW202204377A (es) |
WO (1) | WO2021202494A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
WO2024020376A1 (en) * | 2022-07-22 | 2024-01-25 | University Of Massachusetts | Aav-mediated delivery of osteoblast/osteoclast-regulating mirnas for osteoporosis therapy |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
US5252334A (en) | 1989-09-08 | 1993-10-12 | Cygnus Therapeutic Systems | Solid matrix system for transdermal drug delivery |
JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US5697899A (en) | 1995-02-07 | 1997-12-16 | Gensia | Feedback controlled drug delivery system |
IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
US6001650A (en) | 1995-08-03 | 1999-12-14 | Avigen, Inc. | High-efficiency wild-type-free AAV helper functions |
US5656016A (en) | 1996-03-18 | 1997-08-12 | Abbott Laboratories | Sonophoretic drug delivery system |
US5797898A (en) | 1996-07-02 | 1998-08-25 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
US5783208A (en) | 1996-07-19 | 1998-07-21 | Theratech, Inc. | Transdermal drug delivery matrix for coadministering estradiol and another steroid |
US5779708A (en) | 1996-08-15 | 1998-07-14 | Cyberdent, Inc. | Intraosseous drug delivery device and method |
IL128780A0 (en) | 1996-09-06 | 2000-01-31 | Univ Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase |
US6177403B1 (en) | 1996-10-21 | 2001-01-23 | The Trustees Of The University Of Pennsylvania | Compositions, methods, and apparatus for delivery of a macromolecular assembly to an extravascular tissue of an animal |
US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
EP2338900B1 (en) | 2001-11-13 | 2014-01-01 | The Trustees of The University of Pennsylvania | Adeno-associated virus (AAV) Cy.5 sequences, vectors containing the same and uses thereof |
WO2015164786A1 (en) | 2014-04-25 | 2015-10-29 | University Of Massachusetts | Recombinant aav vectors useful for reducing immunity against transgene products |
PT3137497T (pt) * | 2014-05-02 | 2021-07-12 | Genzyme Corp | Vetores de aav para terapia genética na retina e snc |
US20200316221A1 (en) * | 2016-10-13 | 2020-10-08 | University Of Massachusetts | Aav capsid designs |
CA3040483A1 (en) * | 2016-10-13 | 2018-04-19 | University Of Massachusetts | Aav capsid designs |
-
2021
- 2021-03-30 EP EP21724401.1A patent/EP4126911A1/en active Pending
- 2021-03-30 CN CN202180025786.0A patent/CN115698039A/zh active Pending
- 2021-03-30 KR KR1020227037874A patent/KR20230113689A/ko unknown
- 2021-03-30 CA CA3177182A patent/CA3177182A1/en active Pending
- 2021-03-30 TW TW110111670A patent/TW202204377A/zh unknown
- 2021-03-30 US US17/915,548 patent/US20230138766A1/en active Pending
- 2021-03-30 IL IL296765A patent/IL296765A/en unknown
- 2021-03-30 JP JP2022559694A patent/JP2023529054A/ja active Pending
- 2021-03-30 AU AU2021248577A patent/AU2021248577A1/en active Pending
- 2021-03-30 AR ARP210100790A patent/AR122404A1/es unknown
- 2021-03-30 WO PCT/US2021/024837 patent/WO2021202494A1/en active Application Filing
- 2021-03-30 BR BR112022019304A patent/BR112022019304A2/pt unknown
- 2021-03-30 MX MX2022012279A patent/MX2022012279A/es unknown
-
2022
- 2022-10-27 CO CONC2022/0015313A patent/CO2022015313A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2023529054A (ja) | 2023-07-07 |
TW202204377A (zh) | 2022-02-01 |
KR20230113689A (ko) | 2023-08-01 |
EP4126911A1 (en) | 2023-02-08 |
US20230138766A1 (en) | 2023-05-04 |
WO2021202494A1 (en) | 2021-10-07 |
MX2022012279A (es) | 2023-02-23 |
CN115698039A (zh) | 2023-02-03 |
IL296765A (en) | 2022-11-01 |
AU2021248577A1 (en) | 2022-09-29 |
CA3177182A1 (en) | 2021-10-07 |
AR122404A1 (es) | 2022-09-07 |
BR112022019304A2 (pt) | 2022-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2022015313A2 (es) | Variantes de cápsides de aav y usos de los mismos | |
JP7094236B2 (ja) | 変異aav、及び、細胞、臓器並びに組織への遺伝子導入のための組成物、方法並びに使用法 | |
ES2703814T3 (es) | Terapia génica para la enfermedad de Fabry | |
CL2019002474A1 (es) | Vector clado f de virus adeno-asociado (vaa) y usos relacionados. | |
NZ763018A (en) | Adeno-associated virus variant capsids and methods of use thereof | |
Rapti et al. | Targeted gene therapy for the treatment of heart failure | |
TW201629225A (zh) | 第九因子基因療法 | |
EA202091352A1 (ru) | Генотерапия мукополисахаридоза iiib | |
AR124119A2 (es) | Partículas virales modificadas y usos de estas | |
BR112021021792A2 (pt) | Composições úteis para tratamento de doença de pompe | |
CO2022010227A2 (es) | Proteínas de la cápside de virus adeno-asociados modificadas para la terapia génica ocular y métodos de uso de las mismas | |
KR20220158674A (ko) | Aav5의 단리 및 변형된 vp1 캡시드 단백질 | |
BR112023001418A2 (pt) | Vetor viral adeno-associado para expressão de glut1 e seus usos | |
CL2023001876A1 (es) | Proteínas de la cápside viral con especificidad para las células del tejido cardiaco | |
MX2023002695A (es) | Virus adeno-asociado para la administración de kh902 (conbercept) y usos del mismo. | |
JP2023534452A (ja) | 神経筋障害及び神経運動障害のための遺伝子療法 | |
MX2022015048A (es) | Viriones de virus adenoasociados con variantes de capsides y metodos de uso de estos. | |
US20210123028A1 (en) | Formulation optimization for viral particles | |
UY38881A (es) | Métodos de tratamiento de enfermedades neovasculares oculares utilizando variantes de aav2 que codifican aflibercept | |
PE20212072A1 (es) | Composiciones utiles en el tratamiento de la enfermedad de krabbe | |
AR119955A1 (es) | Métodos de tratamiento de enfermedades neovasculares oculares utilizando variantes de aav2 que codifican aflibercept | |
AR127206A1 (es) | Cápsides de aav novedosas y composiciones que las contienen | |
EA202192973A1 (ru) | Композиции, полезные для лечения болезни помпе | |
BR112023019056A2 (pt) | Métodos para tratar doenças oculares usando variantes de aav2 que codificam aflibercepte | |
AR123245A1 (es) | Nuevas cápsulas de aav y composiciones que las contienen |